Adjunct Therapies In Type 1 Diabetes-Reference-Cited by-同舟云学术

Adjunct Therapies In Type 1 Diabetes

Published:2016-02 Issue:2 Volume:22 Page:277-280
ISSN:1530-891X
Container-title:Endocrine Practice
language:en
Short-container-title:Endocrine Practice

Author:

Dandona Paresh.,Kuhadiya Nitesh D.,Ghanim Husam.,Chaudhuri Ajay.

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism

Reference30 articles.

1. Internal secretion of pancreas;Banting;J Lab Clin Med,1922

2. Insulin: discovery and controversy;Rosenfeld;Clin Chem,2002

3. Glycemic control and excess mortality in type 1 diabetes;Lind;N Engl J Med,2014

4. KuhadiyaND, DhindsaS, GhanimH, MehtaA, et al. Liraglutide as additional treatement to insulin in patients with type 1 diabetes mellitus: a randomized placebo-controlled clinical trial. AACE 2014 Late Breaking Abstract.

5. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes;Whitehouse;Diabetes Care,2002

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Catalyzing beta-cell replacement research to achieve insulin independence in type 1 diabetes: Goals and priorities;Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas;2020

2. Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus;Diabetes, Obesity and Metabolism;2019-03-14

3. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial;The Lancet Diabetes & Endocrinology;2017-11